Walter Reed Army Institute of Research, 503 Robert Grant Avenue, Silver Spring, MD 20910, USA.
Expert Rev Vaccines. 2011 May;10(5):589-99. doi: 10.1586/erv.11.57.
Malaria continues to be a worldwide leading cause of morbidity and mortality, and the development of an effective malaria vaccine remains a research imperative. Of the multiple approaches that have been pursued, the RTS,S/AS01 vaccine candidate represents the most developed and clinically validated malaria vaccine formulation. Throughout its development, increasingly more effective adjuvants have been key in improving the potency of the vaccine. RTS,S-based vaccine formulations have been demonstrated to be safe, well tolerated, immunogenic, and to confer partial efficacy in both malaria-naive and -experienced adults as well as children. Further research to optimize and improve vaccine efficacy is ongoing.
疟疾仍然是全球发病率和死亡率的主要原因，开发有效的疟疾疫苗仍然是研究的当务之急。在已经探索的多种方法中，RTS,S/AS01 疫苗候选物是最成熟和经过临床验证的疟疾疫苗配方。在其发展过程中，越来越有效的佐剂在提高疫苗效力方面发挥了关键作用。基于 RTS,S 的疫苗配方已被证明是安全的、耐受性良好的、具有免疫原性的，并在疟疾初发和经验丰富的成人以及儿童中具有部分疗效。进一步的研究正在优化和提高疫苗的效力。
